Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

360
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
360
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

47
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
47
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

7.9K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
7.9K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.8K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

477
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
477

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of the Pediatric Pharmacist in Precision Medicine and Clinical Pharmacogenomics for Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.

Surgery·2026
Same author

Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy.

Pharmacogenomics·2026
Same author

Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.

Surgical endoscopy·2026
Same author

Prevalence of CYP2C19 phenotypes in patients undergoing a hiatal hernia repair.

Pharmacogenetics and genomics·2026
Same author

Creation of a Merged Harmonized Large Database of Subject-Level Data from Acute Secondary Prevention Studies in Minor Non-Cardioembolic Stroke or TIA.

International journal of cerebrovascular disease and stroke·2026

Related Experiment Video

Updated: Oct 29, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.

Emily J Cicali1,2, Amanda L Elchynski1,2, Kelsey J Cook3,4

  • 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

Clinical Pharmacology and Therapeutics
|July 7, 2021
PubMed
Summary
This summary is machine-generated.

Understanding drug metabolism is key for safe prescribing. This study introduces a calculator to help clinicians assess CYP2D6 phenoconversion, addressing challenges in integrating this important factor into patient care.

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.9K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.9K

Related Experiment Videos

Last Updated: Oct 29, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.9K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.9K

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology

Background:

  • Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) genotype is crucial for medication prescribing.
  • Drug interactions can alter the clinical effect of medications, a phenomenon known as phenoconversion, which differs from genotype-predicted outcomes.
  • Phenoconversion is common but often overlooked in clinical practice due to integration challenges.

Purpose of the Study:

  • To develop a calculator tool for assessing CYP2D6 phenoconversion.
  • To identify key clinical factors for implementing CYP2D6 phenoconversion into practice.
  • To share the methodology used by the University of Florida Health Precision Medicine Program.

Main Methods:

  • Development of a calculator tool to standardize CYP2D6 phenoconversion assessment.
  • Identification of clinical factors influencing CYP2D6 phenoconversion during tool development.
  • Tutorial format to guide clinicians on implementation.

Main Results:

  • A practical calculator tool was created to aid clinicians in assessing CYP2D6 phenoconversion.
  • Several critical clinical factors for implementing phenoconversion assessment were identified.
  • The process and considerations for building the tool are detailed.

Conclusions:

  • Integrating CYP2D6 phenoconversion assessment into clinical practice is feasible with appropriate tools and knowledge.
  • The developed calculator and identified factors can improve the clinical utility of CYP2D6 pharmacogenomics.
  • This work facilitates the adoption of phenoconversion assessment for personalized medicine.